PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Stroke. Author manuscript; available in PMC 2010 August 12.
Published in final edited form as:
PMCID: PMC2920637
NIHMSID: NIHMS109504

Advances in Stroke 2008: Update on the Genetics of Stroke and Cerebrovascular Disease 2008

Martin Dichgans, MD1 and Robert A. Hegele, MD FRCPC FACP2

Whole genome association studies

2008 has brought us the first fruits from genomewide association studies (GWASs), an unbiased and comprehensive approach to identify common risk alleles for complex diseases of adulthood. By genotyping >310,000 single nucleotide polymorphisms (SNPs) in over 1,700 intracranial aneurysm (IA) cases and 7,400 controls from Finland and the Netherlands, a multinational team of investigators recently identified several common SNPs that showed significant association with IA 1. SNPs on chromosomes 2q, 8q and 9p were found to replicate in an independent sample from Japan with similar odds ratios (OR) in all three samples. Pooled OR were between 1.24 and 1.36 and analyses of the combined effects suggested a significant linear relationship with risk score in each cohort, with a more than threefold increase from the lowest to highest strata. Collectively, the three loci were calculated to account for 38-46% of the population–attributable fraction (PAF) of IA, which is substantial. While additional work in other ethnic groups is required, the consistency emphasizes the robustness of the findings.

The critical genetic intervals on chromosomes 8q and 9p both harbour genes that are implicated in the regulation of stem (progenitor) cell populations and expressed in the adult vasculature. SOX17, the main candidate gene on 8q, is required for both endothelial formation and maintenance - an interesting aspect when considering the predominant location of IA at arterial branch points and sites of endothelial shear stress.

The association between common variants at 9p and IA had already been reported in another study earlier last year 2. The 9p21.3 region was originally identified as a major risk locus for coronary artery disease (CAD) and myocardial infarction (MI) 3. Subsequent analyses revealed that the same chromosomal region is also implicated in risk of IA and abdominal aortic aneurysms (AAA). The estimated risk for IA conferred by the main risk allele (rs10757278-G) was very similar across sample sets from Iceland, Finland, and the Netherlands and comparable to that for AAA and CAD. Moreover, the risk of AAA and IA was found to be independent of the risk of CAD, thus indicating a broader role of the 9p21.3 region in arterial disease 2.

Extending these findings, investigators of the international stroke genetics consortium recently demonstrated associations between several SNPs in the 9p21.3 region and large artery stroke 4. The study included 4376 ischemic stroke patients, 970 of whom were classified as having large artery stroke. ORs for the lead SNP (rs1537378-C) were remarkably consistent across populations from different geographical regions and ethnic backgrounds (pooled OR = 1.21). In contrast, no associations were found with other etiological stroke subtypes, thus stressing the specific impact of the 9p21.3 region on large artery disease. The estimate for the PAF was 20%, which renders the 9p21.3 region a major locus for large artery stroke.

The influence of the 9p21.3 region on risk of vascular disease seems to be independent of conventional vascular risk factors. This would suggest that we are dealing with an entirely new risk factor for various arterial phenotypes 2 4. There is some indication that the effects of 9p21.3 are mediated through vascular remodelling. However, additional studies are needed to disentangle the mechanisms leading to such diverse arterial phenotypes. The next challenge now is to identify the responsible genes and associated mechanisms. Positional candidates include CDKN2B (encoding p15INK4b), CDKN2A (encoding p16INGK4a, and ARF) and ANRIL (a non-protein-coding transcript), all of which are expressed in the vasculature. Of interest, p16INGK4a like SOX17 has been shown to be implicated in the regulation of stem (progenitor) cells 5.

Another important finding has been the identification of risk variants for ischemic stroke on chromosome 4q25. Investigators from Iceland, Germany, Sweden and the UK recently reported a multistage GWAS including 6,222 ischemic stroke patients and 29,474 controls. A single SNP (rs2200733-T) on chromosome 4q25 was significantly associated with cardioembolic stroke in various European populations. Again, OR were remarkably similar between samples, the combined OR being 1.52, (p=5.8×10-12)6. The same variant has previously been associated with atrial fibrillation (AF) 7, which suggests that the risk of stroke is mediated through AF, although this was not specifically addressed in the study by Gretarsdottir et al.. Of interest, rs2200733-T was also associated with ischemic stroke not classified as cardioembolic stroke (combined OR= 1.18), suggesting that AF may be underdiagnosed in this group of patients. In theory, genotyping of rs2200733 might help identify subjects at risk for intermittent or future permanent AF. However, it is currently unclear whether such an approach has diagnostic utility 8. Ideally, guidance on the use of gene testing should come from randomized prospective trials (see below).

The above results illustrate the need for cautious phenotyping. Most likely the majority of risk alleles contribute to etiological stroke subtypes rather than stroke per se. Thus, “lumping” stroke subtypes together will attenuate most of the signals in association studies. Analyses according to subtypes pose a challenge to both sample size and phenotyping quality. Sample size issues can be solved by collaborative efforts such as those within the Ischemic Stroke Genetics Consortium (www.strokegenetics.org). In contrast, harmonization of phenotyping protocols and stroke subtype classification between sites remains a major task 9. Standardized data on conventional risk factors, intermediate phenotypes such as intima-media thickness (IMT), infarct volumes and outcomes are desirable but not always possible to obtain. Such data will eventually be needed to disentangle the mechanisms by which genetic variants contribute to stroke risk.

The initial results from GWASs might represent the “low hanging fruit” for genetic susceptibility to stroke although some alleles with moderate relative risks may have gone undetected. Future studies to identify risk alleles with smaller relative risk ratios (say ~1.10 or less) will probably require tens of thousands of patients. While biologically important, the clinical relevance of such markers is currently not clear.

Pharmacogenomics

Recent progress in pharmacogenomics might soon be translatable into the clinic. Two pertinent examples include characterization of genetic differences in sensitivity to anticoagulation by warfarin and the identification of risk alleles for serious myopathy with statins.

Observational studies and randomized trials have shown that genotypes of the cytochrome P450 2C9 gene, CYP2C9, and the vitamin K epoxide reductase complex 1 gene, VKORC1, influence warfarin response across diverse patient groups 10. Furthermore, CYP2C9 variant genotypes are associated with increased risk of serious bleeding events. But despite the excitement about this research, routine genotyping of CYP2C9 and VKORC1 in the general patient population to guide warfarin dosing is not yet supported by current evidence. This might change with accumulation of prospective studies, which are currently underway (www.clinicaltrials.gov).

A common adverse effect encountered in patients taking statins is dose-related myopathy. A recent GWAS showed a strong association of simvastatin-related myopathy with a common SNP located within the drug transporter gene SLCO1B1 11. This SNP had a prevalence of ~15% in the study population and one or two copies of the risk allele increased the odds of severe myopathy by ~4 and ~17-fold, respectively. While these findings might not be generalizable to patients with milder myalgias or to those taking statins other than simvastatin, the study provided proof-of-concept of genetic susceptibility to this adverse effect. In light of the obvious benefit of statin drugs, it is not yet clear whether this SNP should be routinely genotyped, since ~85% of homozygotes for the risk allele tolerated simvastatin without incident. Perhaps the initiation dose of statin could be reduced in genetically predisposed individuals, but even this idea would require further clinical evaluation.

More candidate gene studies in stroke

As illustrated above complex genetics is moving towards unbiased genomewide approaches. Nevertheless, the past year has continued to see numerous candidate gene association studies. A broader theme in many of these studies has been the inflammatory system 12, 13. Thus, for example, investigators from Austria found an association between a deletion mutation in the chemokine receptor CCR5 and a lower risk of incident cardiovascular disease including stroke 14. The same mutation was associated with lower levels of C-reactive protein and a lower carotid IMT, suggesting an intriguing link between the genetic variant, inflammation, an intermediate phenotype and clinical endpoints. However, as always replication in independent cohorts remains the litmus test in genetic association studies 15.

Outlook

Genetics remains a rapidly developing field. The coming months and years will see additional GWASs on ischemic stroke, hemorrhagic stroke, and related phenotypes such as white matter hyperintensities and IMT. Advances in genotyping methodology and analysis tools now also allow for the identification of rare (micro)deletions, duplications and insertions on a genome-wide level. Such variants – collective termed copy numbers variations (CNV) – have recently been recognized to contribute to complex multifactorial disease 16, 17. Rare variants may account for a larger fraction of the overall genetic risk than previously assumed. One example is the recent identification of rare independent mutations in renal salt handling genes contributing to blood pressure variation 18. The most complete profile of genomic differences between patients and controls will eventually come from next-generation whole genome sequencing, which is already within our reach if not our grasp 19. Expectations are high that genetic discoveries will eventually be translated into improved diagnostics and treatment.

Acknowledgments

Supported by grants from the Wellcome Trust (MD).

RAH is supported by the Jacob J. Wolfe Distinguished Medical Research Chair, the Edith Schulich Vinet Canada Research Chair (Tier I) in Human Genetics, a Career Investigator award from the Heart and Stroke Foundation of Ontario, operating grants from the Canadian Institutes for Health Research (MOP-13430, MT-8014), the Heart and Stroke Foundation of Ontario (NA-5320, T-5603, PRG-5967) and by Genome Canada through the Ontario Genomics Institute.

Footnotes

Conflicts of interest statement: The authors have no conflict of interest to declare

Reference List

1. Bilguvar K, Yasuno K, Niemela M, Ruigrok YM, von Und Zu FM, van Duijn CM, van den Berg LH, Mane S, Mason CE, Choi M, Gaal E, Bayri Y, Kolb L, Arlier Z, Ravuri S, Ronkainen A, Tajima A, Laakso A, Hata A, Kasuya H, Koivisto T, Rinne J, Ohman J, Breteler MM, Wijmenga C, State MW, Rinkel GJ, Hernesniemi J, Jaaskelainen JE, Palotie A, Inoue I, Lifton RP, Gunel M. Susceptibility loci for intracranial aneurysm in European and Japanese populations. Nat Genet. 2008 November 9; [PMC free article] [PubMed]
2. Helgadottir A, Thorleifsson G, Magnusson KP, Gretarsdottir S, Steinthorsdottir V, Manolescu A, Jones GT, Rinkel GJ, Blankensteijn JD, Ronkainen A, Jaaskelainen JE, Kyo Y, Lenk GM, Sakalihasan N, Kostulas K, Gottsater A, Flex A, Stefansson H, Hansen T, Andersen G, Weinsheimer S, Borch-Johnsen K, Jorgensen T, Shah SH, Quyyumi AA, Granger CB, Reilly MP, Austin H, Levey AI, Vaccarino V, Palsdottir E, Walters GB, Jonsdottir T, Snorradottir S, Magnusdottir D, Gudmundsson G, Ferrell RE, Sveinbjornsdottir S, Hernesniemi J, Niemela M, Limet R, Andersen K, Sigurdsson G, Benediktsson R, Verhoeven EL, Teijink JA, Grobbee DE, Rader DJ, Collier DA, Pedersen O, Pola R, Hillert J, Lindblad B, Valdimarsson EM, Magnadottir HB, Wijmenga C, Tromp G, Baas AF, Ruigrok YM, van Rij AM, Kuivaniemi H, Powell JT, Matthiasson SE, Gulcher JR, Thorgeirsson G, Kong A, Thorsteinsdottir U, Stefansson K. The same sequence variant on 9p21 associates with myocardial infarction, abdominal aortic aneurysm and intracranial aneurysm. Nat Genet. 2008 February;40(2):217–24. [PubMed]
3. Samani NJ, Erdmann J, Hall AS, Hengstenberg C, Mangino M, Mayer B, Dixon RJ, Meitinger T, Braund P, Wichmann HE, Barrett JH, Konig IR, Stevens SE, Szymczak S, Tregouet DA, Iles MM, Pahlke F, Pollard H, Lieb W, Cambien F, Fischer M, Ouwehand W, Blankenberg S, Balmforth AJ, Baessler A, Ball SG, Strom TM, Braenne I, Gieger C, Deloukas P, Tobin MD, Ziegler A, Thompson JR, Schunkert H. Genomewide association analysis of coronary artery disease. N Engl J Med. 2007 August 2;357(5):443–53. [PMC free article] [PubMed]
4. Gschwendtner A, Bevan S, Cole JW, Plourde A, Matarin M, Ross-Adams H, Meitinger T, Wichmann E, Mitchell BD, Furie KL, Slowik A, Rich S, Syme PD, MacLeod MJ, Meschia JF, Rosand J, Kittner SJ, Markus HS, Müller-Myhsok B, Dichgans M. on behalf of the Interational Stroke Genetics Consortium, gs. Sequence Variants on Chromosome 9p21.3 Confer Risk of Atherosclerotic Stroke. Ann Neurol. 2008 in press. [PMC free article] [PubMed]
5. Janzen V, Forkert R, Fleming HE, Saito Y, Waring MT, Dombkowski DM, Cheng T, DePinho RA, Sharpless NE, Scadden DT. Stem-cell ageing modified by the cyclin-dependent kinase inhibitor p16INK4a. Nature. 2006 September 28;443(7110):421–6. [PubMed]
6. Gretarsdottir S, Thorleifsson G, Manolescu A, Styrkarsdottir U, Helgadottir A, Gschwendtner A, Kostulas K, Kuhlenbaumer G, Bevan S, Jonsdottir T, Bjarnason H, Saemundsdottir J, Palsson S, Arnar DO, Holm H, Thorgeirsson G, Valdimarsson EM, Sveinbjornsdottir S, Gieger C, Berger K, Wichmann HE, Hillert J, Markus H, Gulcher JR, Ringelstein EB, Kong A, Dichgans M, Gudbjartsson DF, Thorsteinsdottir U, Stefansson K. Risk variants for atrial fibrillation on chromosome 4q25 associate with ischemic stroke. Ann Neurol. 2008 November 7;64(4):402–9. [PubMed]
7. Gudbjartsson DF, Arnar DO, Helgadottir A, Gretarsdottir S, Holm H, Sigurdsson A, Jonasdottir A, Baker A, Thorleifsson G, Kristjansson K, Palsson A, Blondal T, Sulem P, Backman VM, Hardarson GA, Palsdottir E, Helgason A, Sigurjonsdottir R, Sverrisson JT, Kostulas K, Ng MC, Baum L, So WY, Wong KS, Chan JC, Furie KL, Greenberg SM, Sale M, Kelly P, MacRae CA, Smith EE, Rosand J, Hillert J, Ma RC, Ellinor PT, Thorgeirsson G, Gulcher JR, Kong A, Thorsteinsdottir U, Stefansson K. Variants conferring risk of atrial fibrillation on chromosome 4q25. Nature. 2007 July 19;448(7151):353–7. [PubMed]
8. Meschia JF. Decoding cryptogenic cardioembolism. Ann Neurol. 2008 August 7;64(4):364–6. [PMC free article] [PubMed]
9. Ay H, Benner T, Arsava EM, Furie KL, Singhal AB, Jensen MB, Ayata C, Towfighi A, Smith EE, Chong JY, Koroshetz WJ, Sorensen AG. A computerized algorithm for etiologic classification of ischemic stroke: the Causative Classification of Stroke System. Stroke. 2007 November;38(11):2979–84. [PubMed]
10. Schwarz UI, Ritchie MD, Bradford Y, Li C, Dudek SM, Frye-Anderson A, Kim RB, Roden DM, Stein CM. Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med. 2008 March 6;358(10):999–1008. [PMC free article] [PubMed]
11. Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F, Gut I, Lathrop M, Collins R. SLCO1B1 variants and statin-induced myopathy--a genomewide study. N Engl J Med. 2008 August 21;359(8):789–99. [PubMed]
12. Fornage M, Chiang YA, O'Meara ES, Psaty BM, Reiner AP, Siscovick DS, Tracy RP, Longstreth WT., Jr Biomarkers of Inflammation and MRI-Defined Small Vessel Disease of the Brain: The Cardiovascular Health Study. Stroke. 2008 July;39(7):1952–9. [PMC free article] [PubMed]
13. Bevan S, Dichgans M, Wiechmann HE, Gschwendtner A, Meitinger T, Markus HS. Genetic variation in members of the leukotriene biosynthesis pathway confer an increased risk of ischemic stroke: a replication study in two independent populations. Stroke. 2008 April;39(4):1109–14. [PubMed]
14. Afzal AR, Kiechl S, Daryani YP, Weerasinghe A, Zhang Y, Reindl M, Mayr A, Weger S, Xu Q, Willeit J. Common CCR5-del32 frameshift mutation associated with serum levels of inflammatory markers and cardiovascular disease risk in the Bruneck population. Stroke. 2008 July;39(7):1972–8. [PubMed]
15. Dichgans M, Markus HS. Genetic association studies in stroke: methodological issues and proposed standard criteria. Stroke. 2005 September;36(9):2027–31. [PubMed]
16. Stefansson H, Rujescu D, Cichon S, Ingason A, Steinberg S, Fossdal R, Sigurdsson E, Sigmundsson T, Buizer-Voskamp JE, Hansen T, Jakobsen KD, Muglia P, Francks C, Matthews PM, Gylfason A, Halldorsson BV, Gudbjartsson D, Thorgeirsson TE, Sigurdsson A, Jonasdottir A, Jonasdottir A, Bjornsson A, Mattiasdottir S, Blondal T, Haraldsson M, Magnusdottir BB, Giegling I, Moller HJ, Hartmann A, Shianna KV, Ge D, Need AC, Crombie C, Fraser G, Walker N, Lonnqvist J, Suvisaari J, Tuulio-Henriksson A, Paunio T, Toulopoulou T, Bramon E, Di FM, Murray R, Ruggeri M, Vassos E, Tosato S, Walshe M, Li T, Vasilescu C, Muhleisen TW, Wang AG, Ullum H, Djurovic S, Melle I, Olesen J, Kiemeney LA, Franke B, Sabatti C, Freimer NB, Gulcher JR, Thorsteinsdottir U, Kong A, Andreassen OA, Ophoff RA, Georgi A, Rietschel M, Werge T, Petursson H, Goldstein DB, Nothen MM, Peltonen L, Collier DA, St CD, Stefansson K. Large recurrent microdeletions associated with schizophrenia. Nature. 2008 September 11;455(7210):232–6. [PMC free article] [PubMed]
17. Mefford HC, Sharp AJ, Baker C, Itsara A, Jiang Z, Buysse K, Huang S, Maloney VK, Crolla JA, Baralle D, Collins A, Mercer C, Norga K, de RT, Devriendt K, Bongers EM, de LN, Reardon W, Gimelli S, Bena F, Hennekam RC, Male A, Gaunt L, Clayton-Smith J, Simonic I, Park SM, Mehta SG, Nik-Zainal S, Woods CG, Firth HV, Parkin G, Fichera M, Reitano S, Lo GM, Li KE, Casuga I, Broomer A, Conrad B, Schwerzmann M, Raber L, Gallati S, Striano P, Coppola A, Tolmie JL, Tobias ES, Lilley C, Armengol L, Spysschaert Y, Verloo P, De CA, Goossens L, Mortier G, Speleman F, van BE, Nelen MR, Hochstenbach R, Poot M, Gallagher L, Gill M, McClellan J, King MC, Regan R, Skinner C, Stevenson RE, Antonarakis SE, Chen C, Estivill X, Menten B, Gimelli G, Gribble S, Schwartz S, Sutcliffe JS, Walsh T, Knight SJ, Sebat J, Romano C, Schwartz CE, Veltman JA, de Vries BB, Vermeesch JR, Barber JC, Willatt L, Tassabehji M, Eichler EE. Recurrent rearrangements of chromosome 1q21.1 and variable pediatric phenotypes. N Engl J Med. 2008 October 16;359(16):1685–99. [PMC free article] [PubMed]
18. Ji W, Foo JN, O'Roak BJ, Zhao H, Larson MG, Simon DB, Newton-Cheh C, State MW, Levy D, Lifton RP. Rare independent mutations in renal salt handling genes contribute to blood pressure variation. Nat Genet. 2008 May;40(5):592–9. [PMC free article] [PubMed]
19. Bentley DR, Balasubramanian S, Swerdlow HP, Smith GP, Milton J, Brown CG, Hall KP, Evers DJ, Barnes CL, Bignell HR, Boutell JM, Bryant J, Carter RJ, Keira CR, Cox AJ, Ellis DJ, Flatbush MR, Gormley NA, Humphray SJ, Irving LJ, Karbelashvili MS, Kirk SM, Li H, Liu X, Maisinger KS, Murray LJ, Obradovic B, Ost T, Parkinson ML, Pratt MR, Rasolonjatovo IM, Reed MT, Rigatti R, Rodighiero C, Ross MT, Sabot A, Sankar SV, Scally A, Schroth GP, Smith ME, Smith VP, Spiridou A, Torrance PE, Tzonev SS, Vermaas EH, Walter K, Wu X, Zhang L, Alam MD, Anastasi C, Aniebo IC, Bailey DM, Bancarz IR, Banerjee S, Barbour SG, Baybayan PA, Benoit VA, Benson KF, Bevis C, Black PJ, Boodhun A, Brennan JS, Bridgham JA, Brown RC, Brown AA, Buermann DH, Bundu AA, Burrows JC, Carter NP, Castillo N, Chiara E, Catenazzi, Chang S, Neil CR, Crake NR, Dada OO, Diakoumakos KD, Dominguez-Fernandez B, Earnshaw DJ, Egbujor UC, Elmore DW, Etchin SS, Ewan MR, Fedurco M, Fraser LJ, Fuentes Fajardo KV, Scott FW, George D, Gietzen KJ, Goddard CP, Golda GS, Granieri PA, Green DE, Gustafson DL, Hansen NF, Harnish K, Haudenschild CD, Heyer NI, Hims MM, Ho JT, Horgan AM, Hoschler K, Hurwitz S, Ivanov DV, Johnson MQ, James T, Huw Jones TA, Kang GD, Kerelska TH, Kersey AD, Khrebtukova I, Kindwall AP, Kingsbury Z, Kokko-Gonzales PI, Kumar A, Laurent MA, Lawley CT, Lee SE, Lee X, Liao AK, Loch JA, Lok M, Luo S, Mammen RM, Martin JW, McCauley PG, McNitt P, Mehta P, Moon KW, Mullens JW, Newington T, Ning Z, Ling NB, Novo SM, O'Neill MJ, Osborne MA, Osnowski A, Ostadan O, Paraschos LL, Pickering L, Pike AC, Pike AC, Chris PD, Pliskin DP, Podhasky J, Quijano VJ, Raczy C, Rae VH, Rawlings SR, Chiva RA, Roe PM, Rogers J, Rogert Bacigalupo MC, Romanov N, Romieu A, Roth RK, Rourke NJ, Ruediger ST, Rusman E, Sanches-Kuiper RM, Schenker MR, Seoane JM, Shaw RJ, Shiver MK, Short SW, Sizto NL, Sluis JP, Smith MA, Ernest Sohna SJ, Spence EJ, Stevens K, Sutton N, Szajkowski L, Tregidgo CL, Turcatti G, Vandevondele S, Verhovsky Y, Virk SM, Wakelin S, Walcott GC, Wang J, Worsley GJ, Yan J, Yau L, Zuerlein M, Rogers J, Mullikin JC, Hurles ME, McCooke NJ, West JS, Oaks FL, Lundberg PL, Klenerman D, Durbin R, Smith AJ. Accurate whole human genome sequencing using reversible terminator chemistry. Nature. 2008 November 6;456(7218):53–9. [PMC free article] [PubMed]